Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
1.91    -0.09 (-4.50%)
Bid:
1.83
Ask:
1.91
Spread: 0.08 (4.372%)
Market Cap: £1.97m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Judgment in Funded Case and Trading Update

19 Jun 2025 07:00

RNS Number : 4712N
Litigation Capital Management Ltd
19 June 2025
 

19 June 2025

 

Litigation Capital Management Limited

("LCM" or the "Company")

 

Judgment in Funded Case and Trading Update

 

Litigation Capital Management Limited ("LCM" or the "Company"), an alternative asset manager specialising in dispute financing solutions internationally, announces that the High Court in London has delivered a judgment in a commercial litigation matter funded by LCM (the "Judgment"). This announcement also includes a trading update for the financial year ending 30 June 2025.

 

Funded Case Judgment

The Judgment found against LCM's funded party. The investment was co-funded alongside Fund I. LCM contributed £3.4m (A$7.2m) of its own capital with a further £8.2m (A$17.2m) invested from Fund I.  As at 31 December 2024, the investment was recorded at a fair value of £5.0m (A$10.1m) on LCM's balance sheet. Adverse costs risk is covered by ATE insurance. LCM is currently reviewing the judgment and assessing potential next steps alongside the funded party and legal representatives.

 

Trading Update

In the second half of the financial year, the number of realisations has been modest with two successful investments and two unsuccessful investments in the period. These realisations in the second half exclude the Judgment noted above and the previously announced Queensland Electricity, Quintis and the commercial arbitration claim; all of which are either subject to appeal processes or considering appeal options.

 

Period

Realisations (A$m)

Invested Capital (A$m)

MOIC multiple

H1 25

52

14

3.7x

H2 25

3

5

0.6x

FY25

55

19

2.9x

 

Note: Invested Capital reflects LCM's investment into the 13 concluded investments. It excludes Queensland Electricity, Quintis, the commercial arbitration and the UK litigation matter referenced above.

 

Net debt is expected to be approximately A$73m at 30 June 2025 (FY24: A$8.9m), reflecting continued deployment into active cases and modest cash inflows during the period. 

 

LCM has received strong interest in Fund III from both existing and new investors. In light of uncertainty surrounding potential tax changes in the US litigation finance market, as well as political developments affecting certain institutional investors, notably US university endowments, LCM considers it prudent to temporarily pause active marketing of Fund III. While LCM has no direct exposure to US tax proposals, maintaining optionality in how we respond to further developments allows us to position the business advantageously as the external environment becomes clearer. We anticipate resuming marketing for Fund III in late 2025 or early 2026 and we remain flexible.

 

In light of this pause, and reflecting the Board's focus on balance sheet discipline following the recently announced trial losses, new commitments for FY25 are expected to be approximately A$80 million (FY24: A$270 million).

 

Management will provide a strategic update with the full year results in September, reflecting on recent developments and outlining the Company's forward priorities. This will include an assessment of the current portfolio, which contains a range of investments at different stages, including several larger matters that have the potential to positively impact future financial performance in a meaningful way.

 

Patrick Moloney, CEO of LCM commented: "This has been a challenging period for LCM, marked by a small number of adverse case outcomes. While the recent trial losses are clearly disappointing, we are actively applying the lessons learned to further strengthen our investment and risk processes. As shareholders would expect, we analyse in detail the reasons for any adverse judgment LCM receives. I look forward to sharing those insights with our investors at our full year results presentation. Fund III marketing has been temporarily paused for the reasons noted but we retain flexibility to recommence that process. We are very pleased with the interest and enthusiasm shown to date by key investors. Our long-term confidence in the fundamentals of the dispute finance sector, and in LCM's differentiated model, remains intact."

 

 

Enquiries

 

Litigation Capital Management

Patrick Moloney, Chief Executive Officer

David Collins, Chief Financial Officer

 

 

Cavendish (Nomad and Joint Broker)

Tel: 020 7523 8000

Jonny Franklin-Adams and Isaac Hooper (Corporate Finance)

Tim Redfern and Jamie Anderson (Corporate Broking)

Canaccord Genuity (Joint Broker)

Tel: 020 7597 5970

Bobbie Hilliam

 

 

NOTES TO EDITORS

Litigation Capital Management (LCM) is an alternative asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

 

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

 

Currently headquartered in Sydney, with offices in London, Singapore and Brisbane, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBDFBKDPAD
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.